Item 2.02. Results of Operations and Financial Condition.

On November 13, 2022, Opiant Pharmaceuticals, Inc. (the "Company"), issued a press release announcing the Company's financial results for the third quarter ended September 30, 2022 and recent corporate highlights. A copy of the press release is furnished herewith as Exhibit 99.1.* * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description


  99.1              Press Release of Opiant Pharmaceuticals, Inc., dated November 13,
                  2022
104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses